Cargando…

Trifluridine/tipiracil as a therapeutic option in real life setting of metastatic colorectal cancer: An efficacy and safety analysis

Background: In the phase III RECOURSE trial, the orally administered combination trifluridine/tipiracil (FTD/TPI) demonstrated a survival benefit and an acceptable safety profile, earning approval as a third-line therapy in metastatic colorectal cancer (mCRC). This study aimed to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sur, Daniel, Lungulescu, Cristina, Spînu, Ștefan, Gorzo, Alecsandra, Dumitrescu, Elena-Adriana, Gheonea, Dan Ionut, Lungulescu, Cristian-Virgil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606616/ https://www.ncbi.nlm.nih.gov/pubmed/36313317 http://dx.doi.org/10.3389/fphar.2022.1041927

Ejemplares similares

Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
por: Gorzo, Alecsandra, et al.
Publicado: (2022)

The Role of Neuropilin-2 in the Epithelial to Mesenchymal Transition of Colorectal Cancer: A Systematic Review
por: Lungulescu, Cristina, et al.
Publicado: (2022)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Rare BRCA2 Mutation and MSI-H in Male Patient with Aggressive Stage III Colorectal Cancer, Case Report and Literature Review
por: GHIMPAU, VALENTINA, et al.
Publicado: (2021)

Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study
por: Chida, Keigo, et al.
Publicado: (2021)

Biomarkers of Trifluridine-Tipiracil Efficacy
por: Voutsadakis, Ioannis A.
Publicado: (2021)

Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
por: Puthiamadathil, Jeevan M, et al.
Publicado: (2017)

Correction to: Trifluridine/Tipiracil: A Review in Metastatic Gastric Cancer
por: Kang, Connie, et al.
Publicado: (2019)

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands
por: Kwakman, Johannes J. M., et al.
Publicado: (2017)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population—A Bi-Institutional Pilot Study
por: Lungulescu, Cristina, et al.
Publicado: (2021)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer
por: Tabernero, Josep, et al.
Publicado: (2017)

Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
por: Malik, Mateusz, et al.
Publicado: (2021)

Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil
por: Koper, Agnieszka, et al.
Publicado: (2023)

Trifluridine/Tipiracil: Old Drug, New Tricks
por: Jeffers, Kate D.
Publicado: (2016)

Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer—A Single UK Centre Experience
por: Tong, Daniel, et al.
Publicado: (2021)

Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan
por: Kagawa, Y., et al.
Publicado: (2023)

Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting
por: Martínez-Lago, Nieves, et al.
Publicado: (2022)

Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
por: Sunakawa, Yu, et al.
Publicado: (2017)

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
por: van de Haar, Joris, et al.
Publicado: (2023)

RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer
por: Koumarianou, Anna, et al.
Publicado: (2023)

Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report
por: Lin, Yu-Lin, et al.
Publicado: (2020)

Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication
por: Nakanishi, Ryota, et al.
Publicado: (2017)

Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
por: Signorelli, Carlo, et al.
Publicado: (2023)

Immunotherapy-Related Publications in Colorectal Cancer: A Bibliometric Analysis
por: Sur, Daniel, et al.
Publicado: (2021)

Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting
por: ELBassiouny, Mohamed
Publicado: (2023)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
por: Yoshino, T., et al.
Publicado: (2020)

Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study
por: Bachet, Jean-Baptiste, et al.
Publicado: (2020)

An Observational Study of Trifluridine/Tipiracil-Containing Regimen Versus Regorafenib-Containing Regimen in Patients With Metastatic Colorectal Cancer
por: Hsieh, Meng-Che, et al.
Publicado: (2022)

Effectiveness, safety, and prognostic factors of trifluridine/tipiracil for the treatment of patients with metastatic colorectal cancer in routine clinical practice
por: Martínez-Pérez, Julia, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
por: Voutsadakis, Ioannis A.
Publicado: (2023)

Long Term Administration of Nivolumab for Metastatic Melanoma: A Case Report
por: Oprea, Adela-Raluca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2hhdsmta4q4ls0fsora2s7tss6